Zerr, Inga
Villar-Piqué, Anna
Hermann, Peter
Schmitz, Matthias
Varges, Daniela
Ferrer, Isidre
Riggert, Joachim
Zetterberg, Henrik
Blennow, Kaj
Llorens, Franc
Funding for this research was provided by:
Instituto de Salud Carlos III (PI19/00144)
Robert Koch institute (1369-341)
Fondo Europeo de Desarrollo Regional (POCTEFA 2014-2020)
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (2018-BP-00129)
Swedish Research Council (2018-02532)
H2020 European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862)
Swedish Research Council (2017-00915)
Alzheimer Drug Discovery Foundation (RDAPB-201809-2016615)
Swedish Alzheimer Foundation (AF-742881)
Hjärnfonden (FO2017-0243)
ALF-agreement (ALFGBG-715986)
EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
Article History
Received: 29 September 2020
Accepted: 23 March 2021
First Online: 21 April 2021
Declarations
:
: The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines and was approved by all local Ethics committees (reference numbers 11/11/93, 5/09/08, 9/06/08, 19/11/09 University Medical School, Göttingen, Germany). All study participants or their legal guardians provided written informed consent.
: Not applicable.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.